Oxaliplatin Injection
Phase 3
Oxaliplatin Injection is one of 84 therapeutic programs targeting Adenocarcinoma. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
83
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
337 competitors in Adenocarcinoma
#DrugCompanyPhaseTrials
1Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Taxol
TevaPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Taxotere
AAvyxa
Phase 3
Beyfortus
BeiGenePhase 3
Cyramza
Eli LillyPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
DATROWAY
Daiichi SankyoPhase 3
Adrucil
EElorac, Inc.
Phase 3
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Adenocarcinoma1 trial
A Randomized, Open-Label, Multicenter Phase III Study of Tecotabart Vedotin Plus Tislelizumab Versus Tislelizumab Plus Chemotherapy as First-Line Treatment in Patients With CLDN18.2-Positive, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Recruiting·SShanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.·Phase 3·NCT07385703·752 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Oxaliplatin Injection. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]